Radiation Injury - Pipeline Review, H1 2018

April 2018 | 46 pages | ID: RED083270A6EN
Global Markets Direct

Abstracts

Radiation Injury - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Injury - Pipeline Review, H1 2018, provides an overview of the Radiation Injury (Toxicology) pipeline landscape.

Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high doses, whole-body exposure causes acute radiation illness, and partial-body exposure causes local radiation injury.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Injury - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Radiation Injury (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Injury (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiation Injury (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Injury (Toxicology).
• The pipeline guide reviews pipeline therapeutics for Radiation Injury (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Radiation Injury (Toxicology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Radiation Injury (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Injury (Toxicology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Radiation Injury (Toxicology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Radiation Injury (Toxicology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Radiation Injury - Overview
Radiation Injury - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Radiation Injury - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Radiation Injury - Companies Involved in Therapeutics Development
FirstString Research Inc
PharmaIN Corp
Synedgen Inc
Tonix Pharmaceuticals Holding Corp
Windtree Therapeutics Inc
Radiation Injury - Drug Profiles
Aerosurf - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-2E2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-2E5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Des-Asp Angiotensin 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DG-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSJ-0017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Prostate Cancer, Asthma and Radiation Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYGN-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Radiation Injury - Dormant Projects
Radiation Injury - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Table 1: Number of Products under Development for Radiation Injury, H1 2018
Table 2: Number of Products under Development by Companies, H1 2018
Table 3: Number of Products under Development by Universities/Institutes, H1 2018
Table 4: Products under Development by Companies, H1 2018
Table 5: Products under Development by Universities/Institutes, H1 2018
Table 6: Number of Products by Stage and Target, H1 2018
Table 7: Number of Products by Stage and Mechanism of Action, H1 2018
Table 8: Number of Products by Stage and Route of Administration, H1 2018
Table 9: Number of Products by Stage and Molecule Type, H1 2018
Table 10: Radiation Injury - Pipeline by FirstString Research Inc, H1 2018
Table 11: Radiation Injury - Pipeline by PharmaIN Corp, H1 2018
Table 12: Radiation Injury - Pipeline by Synedgen Inc, H1 2018
Table 13: Radiation Injury - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2018
Table 14: Radiation Injury - Pipeline by Windtree Therapeutics Inc, H1 2018
Table 15: Radiation Injury - Dormant Projects, H1 2018
Table 16: Radiation Injury - Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Figure 1: Number of Products under Development for Radiation Injury, H1 2018
Figure 2: Number of Products under Development by Companies, H1 2018
Figure 3: Number of Products by Targets, H1 2018
Figure 4: Number of Products by Stage and Targets, H1 2018
Figure 5: Number of Products by Mechanism of Actions, H1 2018
Figure 6: Number of Products by Stage and Mechanism of Actions, H1 2018
Figure 7: Number of Products by Routes of Administration, H1 2018
Figure 8: Number of Products by Stage and Routes of Administration, H1 2018
Figure 9: Number of Products by Molecule Types, H1 2018
Figure 10: Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

FirstString Research Inc
PharmaIN Corp
Synedgen Inc
Tonix Pharmaceuticals Holding Corp
Windtree Therapeutics Inc